Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

676495 VEGF Inhibitor, V1 - Calbiochem

The VEGF Inhibitor, V1 controls the biological activity of VEGF. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

VEGF Inhibitor, V1 - Calbiochem : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: ATWLPPR

Primary Target: Specifically competes against VEGF165 binding to recombinant NRP-1
676495
Purchase on Sigma-Aldrich

Aperçu

Replacement Information

Tableau de caractéristiques principal

Empirical Formula
C₄₀H₆₁N₁₁O₉

Products

RéférenceConditionnement Qté
676495-1MG Ampoule plast. 1 mg
Description
OverviewAn NRP-1-binding heptapeptide whose target was initially mistaken as VEGFR2/KDR/Flk-1 due to its binding activity to a CHO-KDR culture that was later shown to express primarily NRP-1 and little KDR. V1/A7R specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays (IC50 = 60 µM), while exhibiting no activity against the interaction between NRP-1 and heparin or VEGF165 binding to KDR, VEGFR1/Flt-1, and heparin. V1/A7R is demonstrated to inhibit VEGF-dependent angiogenesis activity in HMVEC (IC50 = 0.3 µM) and HUVEC cultures in vitro, as well as in a rabbit corneal neovascularization model and in mice bearing MDA-MB-231-derived tumor in vivo.
Catalogue Number676495
Brand Family Calbiochem®
SynonymsATWLPPR
References
ReferencesStarzec, A., et al. 2006. Life Sci. 79, 2370.
Binetruy-Tournaire, R., et al. 2000. EMBO J. 19, 1525.
Product Information
ATP CompetitiveN
FormWhite lyophilized solid
FormulationSupplied as a trifluoroacetate salt.
Hill FormulaC₄₀H₆₁N₁₁O₉
Chemical formulaC₄₀H₆₁N₁₁O₉
Hygroscopic Hygroscopic
ReversibleN
Quality LevelMQ100
Applications
Biological Information
Primary TargetSpecifically competes against VEGF165 binding to recombinant NRP-1
Primary Target IC<sub>50</sub>60 µM for specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays
Purity≥95% by HPLC
Physicochemical Information
Cell permeableN
Peptide SequenceH-Ala-Thr-Trp-Leu-Pro-Pro-Arg-OH
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Hygroscopic Hygroscopic
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Référence GTIN
676495-1MG 04055977260472

Documentation

VEGF Inhibitor, V1 - Calbiochem FDS

Titre

Fiche de données de sécurité des matériaux (FDS) 

VEGF Inhibitor, V1 - Calbiochem Certificats d'analyse

TitreNuméro de lot
676495

Références bibliographiques

Aperçu de la référence bibliographique
Starzec, A., et al. 2006. Life Sci. 79, 2370.
Binetruy-Tournaire, R., et al. 2000. EMBO J. 19, 1525.
Fiche technique

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision10-June-2009 RFH
SynonymsATWLPPR
DescriptionAn NRP-1-binding heptapeptide whose target was initially mistaken as VEGFR2/KDR/Flk-1 due to its binding activity to a CHO-KDR culture that was later shown to express primarily NRP-1 and little KDR. V1/A7R specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays (IC50 = 60 µM), while exhibiting no activity against the interaction between NRP-1 and heparin or VEGF165 binding to KDR, VEGFR1/Flt-1, and heparin. V1/A7R is demonstrated to inhibit VEGF-dependent angiogenesis activity in HMVEC (IC50 = 0.3 µM) and HUVEC cultures in vitro, as well as in a rabbit corneal neovascularization model and in mice bearing MDA-MB-231-derived tumor in vivo.
FormWhite lyophilized solid
FormulationSupplied as a trifluoroacetate salt.
Intert gas (Yes/No) Packaged under inert gas
Chemical formulaC₄₀H₆₁N₁₁O₉
Peptide SequenceH-Ala-Thr-Trp-Leu-Pro-Pro-Arg-OH
Purity≥95% by HPLC
SolubilityDMSO (5 mg/ml)
Storage +2°C to +8°C
Hygroscopic
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesStarzec, A., et al. 2006. Life Sci. 79, 2370.
Binetruy-Tournaire, R., et al. 2000. EMBO J. 19, 1525.